BIOMERICA INC. DL-,08

Biomerica presented on October 14, 2025 the figures for the quarter ended August 31, 2025. Revenue amounted to $1.4 million, 23.76% below the prior-year level of $1.8 million. » Mere på finanzen.net

Biomerica has introduced the "inFoods IBS Trigger Food Navigator," an AI-powered digital tool that uses existing inFoods IBS test results to provide patients with personalized dietary and menu suggestions as well as intelligent food recognition. The tool was developed with nutrition scientists from the University of Michigan and is available at no extra cost to existing test customers. A published study shows that 59.6% of patients achieved significant pain relief by avoiding identified triggers, with even higher rates for constipation-predominant and mixed IBS types. Despite strong liquidity, the company’s gross margin remains low; with annual revenue of $5.31 million, it still sees substantial market potential. » Mere på de.investing.com

The United Arab Emirates Ministry of Health has approved Biomerica Inc.'s Fortel kidney test for home use; the 10-minute test detects early albumin in urine and is aimed at people with diabetes and hypertension. Biomerica plans to distribute the test through partners in pharmacies, clinics and hospitals in the UAE, strengthening its presence in the Middle East; additional product approvals and personnel announcements were also made (Chief Commercial Officer Scott Madel, board member Eric B. Chin). International study results and high regional prevalence rates of diabetes and hypertension reinforce the test's market relevance. » Mere på de.investing.com